Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Lymphoma 549Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Lymphoma, Non-Hodgkin 437Lymphoma, Follicular 405Lymphoma, Large B-Cell, Diffuse 392Leukemia, Lymphocytic, Chronic, B-Cell 392Lymphoma, B-Cell 248Lymphoma, Mantle-Cell 224Hodgkin Disease 209Recurrence 205Leukemia, Myeloid, Acute 199Leukemia 196Multiple Myeloma 185Burkitt Lymphoma 185Lymphoma, B-Cell, Marginal Zone 170Neoplasms 153Myelodysplastic Syndromes 134Hematologic Neoplasms 115Waldenstrom Macroglobulinemia 103Lymphoma, T-Cell, Peripheral 86Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, T-Cell 82Lymphoma, T-Cell, Cutaneous 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Mycosis Fungoides 57Leukemia, Biphenotypic, Acute 55Breast Neoplasms 55Leukemia, B-Cell 52Myeloproliferative Disorders 50Lymphoproliferative Disorders 47

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × Lymphoid × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡